MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务。
CAS No. : 1570496-34-2
MCE 国际站:IACS-010759
产品活性:IACS-010759 是一种口服有效的线粒体氧化磷酸化复合物 I (OXPHOS) 抑制剂。IACS-010759 在依赖 OXPHOS 的脑癌和急性髓性白血病 (AML) 模型中抑制增殖并诱导细胞凋亡。IACS-010759 具有用于复发/难治性 AML 和实体瘤研究的潜力。
研究领域:Metabolic Enzyme/Protease | Apoptosis
作用靶点:Mitochondrial Metabolism | Apoptosis
In Vitro: IACS-010759 (10, 30, 100?nM; for 4 or 5 days) reduces viability and induces apoptosis in primary AML.
?IACS-010759 (0.001, 0.01, 0.1, 1, 10, 100, 1000 nM; 72 hurs) robustly inhibits both OCR and galactose-dependent H460 cell viability and has nearly identical IC50 values of 1.4?nM.
?IACS-010759 is similarly active in mouse (average IC50?=?5.6?nM), rat (IC50?=?12.2?nM), and cynomolgus monkey (IC50?=?8.7?nM) cell lines.
?IACS-010759 (0.01-10 μM) yieldes a maximal reduction of growth of?>?50% in the majority of cancer cell lines (24 of 30 pancreatic (PDAC), 19 of 20 ovarian, 13 of 16 triple-negative breast (TNBC), 8 of 10 non-small-cell lung (NSCLC)) and a subset (11of 30 PDAC, 10 of 20 ovarian, 5 of 16 TNBC, 2 of 10 NSCLC) exhibited?>?100% growth inhibition.
In Vivo: IACS-010759 (5, 10, 25?mg/kg/day; oral; for 21 d) results in tumor regression with minimal body weight loss at the 5 or 10?mg/kg dose in mice bearing NB-1 (PGD-null) subcutaneous xenografts. IACS-010759 at the 25?mg/kg dose is not tolerated.
?IACS-010759 HCl (10?mg/kg; orally; QD (daily) or QD×5 (5 d on/2 d off); for 35 d) increases median survival from 28 d to longer than 60 d, whereas less-frequent dosing schedules (Q2D or Q3D) enhances survival to a lesser extent.
?IACS-010759 (0.3?mg/kg for iv; 1?mg/kg for oral) has low plasma clearance with a high volume of distribution, resulting in a prolonged terminal half-life (>24?h).
相关产品:Clinical Compound Library Plus | Bioactive Compound Library Plus | Apoptosis Compound Library | Metabolism/Protease Compound Library | Stem Cell Signaling Compound Library | Anti-Cancer Compound Library | Clinical Compound Library | Anti-Aging Compound Library | Reprogramming Compound Library | Orally Active Compound Library | Glutamine Metabolism Compound Library | Anti-Lung Cancer Compound Library | Anti-Pancreatic Cancer Compound Library | Anti-Blood Cancer Compound Library | Anti-Cancer Metabolism Compound Library | Anti-Parkinson's Disease Compound Library | Neurodegenerative Disease-related Compound Library | Mitochondria-Targeted Compound Library | Glucose Metabolism Compound Library | Cuproptosis Compound Library | Cancer Stem Cells Compound Library | Heterocyclic Compound Library | Mitochondrial Protection Compound Library | SY-5609 | BRD4 Inhibitor-18 | 8α-Tigloyloxyhirsutinolide 13-O-acetate | AAPK-25 | Dutasteride-13C6 | Oleic acid-13C | Anticancer agent 120 | Abacavir sulfate | Meloxicam-d3-1 | Thailanstatin D | SB-218078 | Toyocamycin | Sorafenib-d4 | Busulfan | PTC-028 | Dinaciclib | CR-1-31-B | 142I5 | Farudodstat | Ecteinascidin 770 | AT9283 | Staurosporine | SNS-032 | AZA1 | Antitumor agent-96 | Bleomycin A5 | Xevinapant | Mangiferin | Cambinol | hGGPPS-IN-1
热门产品线:重组蛋白 | 化合物库 | 天然产物 | 荧光染料 | PROTAC | 同位素标记物 | 寡核苷酸 | 抗体 | 点击化学
Trending products:Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Fluorescent Dye | PROTAC | Isotope-Labeled Compounds | Oligonucleotides | Antibodies | Click Chemistry
货号: HY-112037
品牌介绍:
• MCE (MedChemExpress) 拥有200 多种全球独家化合物库,我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物;
• 50,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领;
• 产品种类涵盖各种重组蛋白,多肽,常用试剂盒 ,更有 PROTAC、ADC 等特色产品,广泛应用于新药研发、生命科学等科研项目;
• 提供虚拟筛选,离子通道筛选,代谢组学分析检测分析,药物筛选等专业技术服务;
• 设有专业的实验中心和严格的质控、验证体系;
• 提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告,确保产品的高纯度、高品质;
• 产品的生物活性多经各国客户实验验证;
• Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果;
• 专业团队跟踪最新的制药及生命科学研究进展,为您提供全球最新的活性化合物;
• 与世界各大制药公司及知名科研机构建立了长期的合作。